How to Safely Stop Atorvastatin (Lipitor): A Step-by-Step Discontinuation Guide
HealthRX.com
Stopping atorvastatin: the label sets triggers, not a taper
At a glance
- Drug / Atorvastatin (Lipitor), an HMG-CoA reductase inhibitor (statin) [1]
- Taper schedule in the label / None described [1]
- Half-life / About 14 hours for atorvastatin; 20 to 30 hours for its inhibitory activity [1]
- LDL-C reduction while taking / 39% at 10 mg to 60% at 80 mg in pooled 6-week data [1]
- Label stop triggers / Markedly elevated CK, suspected myopathy, suspected immune-mediated necrotizing myopathy, serious liver injury [1]
- Most common adverse reaction leading to discontinuation / Myalgia, affecting 0.7% of Lipitor-treated patients (a rate greater than placebo) [1]
- Pregnancy / Discontinue when recognized, or weigh ongoing need; not a contraindication [1]
- Prescription status / Prescription only [1]
Is a taper needed to stop atorvastatin?
The Lipitor label has no tapering instructions. It describes the drug as once daily at any time of day, with or without food, and it discusses stopping only in the context of specific problems [1].
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate, a cholesterol precursor. In animal models it lowers plasma cholesterol by inhibiting hepatic cholesterol synthesis and raising the number of hepatic LDL receptors, which increases LDL uptake and breakdown [1]. Atorvastatin has a half-life of about 14 hours, and its inhibitory activity, including that of its active metabolites, has a half-life of 20 to 30 hours [1].
What people on Reddit report
Reddit accounts from people who stopped a statin, some on Lipitor, and asked whether stopping causes rebound cholesterol, withdrawal or worse symptoms. Experiences and opinions differ.
When you quit a statin LDL will likely go back up.Read the source discussion
I have not heard or read documentation showing any harm from coming off of statins suddenly.Read the source discussion
I just stopped about a week ago. Have been on Lipitor for 10+ years. Having withdrawal.Read the source discussion
I was told my my doctor that I could just quit it cold turkey.Read the source discussion
When the Lipitor label says to stop
The label's stopping language is a set of triggers, not a schedule:
- Muscle problems. The label says to discontinue Lipitor if markedly elevated CK levels occur or if myopathy is diagnosed or suspected, and it notes that muscle symptoms and CK elevations may resolve if the drug is discontinued [1].
- Immune-mediated necrotizing myopathy. The label calls for discontinuation if this is suspected. It is an autoimmune myopathy with proximal weakness and elevated CK that persists despite stopping the statin, a positive anti-HMG-CoA reductase antibody, and improvement with immunosuppressive treatment [1].
- Serious liver injury. If hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, the label says to promptly discontinue atorvastatin [1]. Acute liver failure and decompensated cirrhosis are contraindications [1].
- Acute or serious illness. The label calls for temporarily stopping Lipitor during an acute or serious condition that carries a high risk of renal failure secondary to rhabdomyolysis; major surgery, sepsis and shock are among its examples [1].
- Pregnancy. The label says to discontinue when pregnancy is recognized, or alternatively to consider the ongoing therapeutic needs of the patient [1]. Pregnancy is not listed as a contraindication, and observational data over decades of use have not identified a drug-associated risk of major congenital malformations [1]. Breastfeeding is not recommended during treatment [1].
- Hypersensitivity. A contraindication, with anaphylaxis, angioneurotic edema, erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis reported [1].
Questions worth asking
What stopping gives up
Atorvastatin is labeled to reduce the risk of myocardial infarction, stroke, revascularization and angina in adults with multiple CHD risk factors but no clinically evident CHD; to reduce MI and stroke in adults with type 2 diabetes and multiple risk factors; and to reduce nonfatal MI, stroke, revascularization, heart-failure hospitalization and angina in adults with established CHD. It is also used, with diet, to lower LDL-C in primary hyperlipidemia, familial hypercholesterolemia, primary dysbetalipoproteinemia and hypertriglyceridemia [1].
The size of the effect depends on dose. In pooled 6-week data, atorvastatin lowered LDL-C by 39% at 10 mg, 43% at 20 mg, 50% at 40 mg and 60% at 80 mg, against a 4% rise on placebo [1].
Two outcome trials show what that effect looks like over years. In TNT, 10,001 patients with stable CHD took 80 mg or 10 mg; after a median 4.9 years a first major cardiovascular event had occurred in 8.7% on 80 mg versus 10.9% on 10 mg (HR 0.78, 95% CI 0.69 to 0.89), a 2.2 percentage point absolute difference, with no difference in overall mortality [3]. In ASCOT-LLA, 10,305 hypertensive patients aged 40 to 79 with at least three other cardiovascular risk factors and total cholesterol of 6.5 mmol/L or less took 10 mg or placebo, and treatment was stopped at a median of 3.3 years: nonfatal MI plus fatal CHD occurred 100 times on atorvastatin versus 154 times on placebo (HR 0.64, 95% CI 0.50 to 0.83) [4].
The PRISM withdrawal signal
PRISM studied 1,616 patients with coronary artery disease and chest pain in the previous 24 hours, recording death and nonfatal MI over 30 days. In the 86 patients whose statin was withdrawn after hospital admission, cardiac risk was higher than in patients who continued a statin (hazard ratio 2.93, 95% CI 1.64 to 6.27) and tended to be higher than in patients who never received one (1.69, 95% CI 0.92 to 3.56; not statistically significant). Statin therapy was associated with fewer events than no statin (adjusted hazard ratio 0.49, 95% CI 0.21 to 0.86) [2].
The excess events clustered in the first week after symptoms began and were independent of cholesterol levels [2]. This was an observational comparison, not a randomized test of stopping, and the withdrawal group was small [2].
LDL-C after the last dose
The label records the size of the treatment effect measured while patients were taking the drug, dose by dose, but it gives no LDL-C data after stopping and no tapering schedule [1]. Its only timing instruction concerns starting treatment: assess LDL-C as early as 4 weeks after beginning atorvastatin and adjust the dose if needed [1].
Muscle symptoms and liver enzymes: what the trials recorded
In 17 placebo-controlled trials with a median 53 weeks of treatment, 8,755 patients took Lipitor at any dose and 7,311 took placebo. Myalgia was reported by 3.5% versus 3.1%, muscle spasms by 3.6% versus 3.0%, and arthralgia by 6.9% versus 6.5% [1].
The adverse reactions most often leading to discontinuation that occurred more often than with placebo were myalgia (0.7% of Lipitor-treated patients), diarrhea (0.5%), nausea (0.4%), alanine aminotransferase increase (0.4%) and hepatic enzyme increase (0.4%) [1]. In TNT, discontinuation for adverse reactions was 9.9% on 80 mg versus 8.1% on 10 mg, persistent transaminase elevations 1.3% versus 0.2%, and CK of 10 times the upper limit of normal or more 0.3% versus 0.1% [1].
Across the clinical trial program, persistent transaminase rises above 3 times the upper limit of normal occurred in about 0.7% of patients, and the rate rose with dose: 0.2% at 10 mg, 0.2% at 20 mg, 0.6% at 40 mg and 2.3% at 80 mg [1].
Every-other-day dosing in a small pilot
One small randomized pilot, the ADDAS study, assigned 35 patients with hyperlipidemia to 10 mg of atorvastatin daily or every other day, doubling the dose if the LDL-C goal was not met. At 6 weeks LDL-C had fallen 27% in the every-other-day group and 38% in the daily group; at 12 weeks the reductions were 35% and 38% (P=0.49). The mean dose at 12 weeks was 18 mg on alternate days (9 mg per day) versus 12 mg per day [5]. The label describes atorvastatin as a once-daily drug [1].
Check what you know
Question 1 of 5
Score: 0 right, 0 of 5 answered
Lipitor blood level falling after the last of its daily doses
After the last dose (dose 4)
atorvastatin (Lipitor tablets)a dose
atorvastatin (Lipitor tablets): 0% of its steady-state peak at the end of week 2; highest that week 1%.
Daily dosing gives a rise to a peak within 1 to 2 hours, with 1.5 hours used for the curve. Because the half-life of about 14 hours is shorter than the once daily interval, the level drops well before the next dose, so each day looks much alike. After dose number 4 the level simply declines. The label says the half-life of enzyme-blocking activity is 20 to 30 hours because of active metabolites, which concerns effect rather than level.
| Elimination half-life | approximately 14 hours (For the drug itself) |
|---|---|
| Half-life of its enzyme-blocking activity | 20 to 30 hours (Longer because of active metabolites) |
| Time to peak after a dose | within 1 to 2 hours (Midpoint of 1.5 hours used for the curve) |
| Dosing interval | once daily |
Week by week numbers
| Week | atorvastatin (Lipitor tablets): highest, then end of week |
|---|---|
| 1 | 99%, 1% |
| 2 | 1%, 0% |
Frequently asked questions
Can I just stop atorvastatin cold turkey?
Will my cholesterol go back up if I stop atorvastatin?
Do muscle symptoms go away after stopping atorvastatin?
Can I take atorvastatin every other day rather than stop it?
Does the label ever call for pausing atorvastatin during an acute illness or major surgery?
How long does atorvastatin stay in the body?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
How to wean off taking atorvastatin?
The Lipitor label gives no tapering schedule. It describes stopping only as triggers, such as markedly elevated CK, suspected myopathy, serious liver injury, or an acute serious illness. In PRISM, the 86 patients whose statin was withdrawn after hospital admission had higher cardiac risk than those who continued (hazard ratio 2.93, 95% CI 1.64 to 6.27), but that study did not test a taper.
Is it okay to take a break from statins?
This is not established. The label lists stop triggers rather than planned breaks, and it gives no LDL-C data after stopping. The LDL-C reductions it reports were measured only while patients were taking the drug. In TNT, first major cardiovascular events occurred in 8.7% on 80 mg versus 10.9% on 10 mg over a median 4.9 years.
Are cholesterol meds bad for you?
The trial data record side effects but do not render a verdict on whether cholesterol drugs are bad for you. In 17 placebo-controlled trials, myalgia was reported by 3.5% of Lipitor patients versus 3.1% on placebo. Myalgia was the adverse reaction most often leading to discontinuation that occurred more often than with placebo, at 0.7%. Persistent transaminase rises above 3 times the upper limit of normal occurred in about 0.7% of patients overall, rising to 2.3% at 80 mg.
Can I quit statins once LDL is controlled ?
This is not established. LDL-C reductions were measured while patients took the drug, and the label gives no LDL-C data after stopping. The cardiovascular benefits in TNT and ASCOT-LLA were observed during treatment, and no data are reported on what happens to that benefit after quitting.
What are the bad side effects of atorvastatin?
The adverse reactions most often leading to discontinuation that occurred more often than with placebo were myalgia (0.7% of Lipitor-treated patients), diarrhea (0.5%), nausea (0.4%), alanine aminotransferase increase (0.4%) and hepatic enzyme increase (0.4%). Persistent transaminase rises above 3 times the upper limit of normal occurred in about 0.7% of patients, and the rate rose with dose.
References
Show all 7 referencesHide references
- U.S. National Library of Medicine, DailyMed. Lipitor atorvastatin calcium tablets (Viatris Specialty) prescribing information. Lipitor atorvastatin calcium tablets (Viatris Specialty) label
- Heeschen C, Hamm CW, Laufs U, Snapinn S, Böhm M, White HD, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002;105(12):1446-52.
- LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-35.
- Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149-58.
- Matalka MS, Ravnan MC, Deedwania PC. Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS). Am Heart J. 2002;144(4):674-7.
- Reddit participants. Can I quit statins once LDL is controlled ? (r/Cholesterol). Accessed 2026-11-10.
- Reddit participants. Are you supposed to taper off statins? (r/Cholesterol). Accessed 2026-11-10.
